Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Mar Tintore Clear advanced filters

  • 2013 witnessed advances in many aspects of multiple sclerosis (MS) research. Two studies highlighted a potential role for salt as an MS trigger, and one immunomodulatory drug performed well in clinical trials. Moreover, treatment effects of MS drugs were shown to correlate inversely with brain atrophy and disease progression.

    • Xavier Montalban
    • Mar Tintoré
    News & Views
    Nature Reviews Neurology
    Volume: 10, P: 72-73

  • Lesion location might turn out to be an important factor in long-term disability prediction in patients with primary progressive multiple sclerosis (MS). Using a lesion probability mapping approach, researchers have identified brain regions where the presence of MS lesions predicts an early need for bilateral walking support.

    • Jaume Sastre-Garriga
    • Mar Tintoré
    News & Views
    Nature Reviews Neurology
    Volume: 6, P: 648-649

  • Real-world observational studies have the potential to answer questions about multiple sclerosis (MS) treatment that randomized controlled trials cannot. Trojano and colleagues discuss the pitfalls and necessary safeguards in observational studies, and the insights that such studies have provided into treatment decisions for patients with MS.

    • Maria Trojano
    • Mar Tintore
    • Helmut Butzkueven
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 105-118

  • The development of treatment for multiple sclerosis over the past 25 years is a success of translational medicine. In this Timeline article, Tintore et al. chart major developments and discuss the implications for current and future patient management.

    • Mar Tintore
    • Angela Vidal-Jordana
    • Jaume Sastre-Garriga
    Reviews
    Nature Reviews Neurology
    Volume: 15, P: 53-58

  • Recently published findings from the ENDORSE study provide 5 years of randomized safety and efficacy data for two doses of dimethyl fumarate (DMF) in multiple sclerosis. The report complements results from the pivotal CONFIRM and DEFINE trials; however, postmarketing data from clinical practice is needed to complete the risk–benefit profile of DMF.

    • Mar Tintoré
    • Jaume Sastre-Garriga
    News & Views
    Nature Reviews Neurology
    Volume: 12, P: 436-437

  • The use of MRI in patients with multiple sclerosis (MS) is commonplace in clinical settings. However, the precise implementation of MRI in the diagnosis of MS is highly variable, which is problematic in the context of the substantial technical advances of the past decade. In these Evidence-based Guidelines, members of the MAGNIMS study group present a standardized approach to the use of MRI in the diagnosis of MS.

    • Àlex Rovira
    • Mike P. Wattjes
    • Xavier Montalban
    ReviewsOpen Access
    Nature Reviews Neurology
    Volume: 11, P: 471-482

  • In the second part of the MAGNIMS network's evidence-based guidelines, Wattjes and colleagues discuss the use of MRI in prognostication and follow-up in patients with multiple sclerosis. The group recommend several techniques that are useful for monitoring disease activity and treatment efficacy, and identify those techniques that require further study.

    • Mike P. Wattjes
    • Àlex Rovira
    • Xavier Montalban
    ReviewsOpen Access
    Nature Reviews Neurology
    Volume: 11, P: 597-606

  • Approximately half of the people currently with multiple sclerosis (MS) are ≥50 years of age, yet guidelines for management of MS in older age are lacking. This Consensus statement presents the outcomes of an International Advisory Committee on Clinical Trials (IACCT) in MS workshop on ageing and MS, including recommendations for advancing research, care and awareness.

    • Anneke van der Walt
    • Eva M. M. Strijbis
    • Yinan Zhang
    Reviews
    Nature Reviews Neurology
    Volume: 21, P: 432-448

  • Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for some forms of multiple sclerosis (MS), but uncertainties remain about its implementation in clinical practice and treatment protocols need to be optimized. This Consensus Statement provides guidance and recommendations for the use of AHSCT in MS and neuromyelitis optica spectrum disorders.

    • Paolo A. Muraro
    • Alice Mariottini
    • Helene Zephir
    Reviews
    Nature Reviews Neurology
    Volume: 21, P: 140-158